Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949659 | 1.00 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL28995745 | 1.00 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1439401 | 1.00 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1722643 | 1.00 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL10238568 | 1.00 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL8759154 | 0.89 | CYP1A2 (0.41) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL12300132 | 0.88 | CYP1A2 (0.42) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL8006914 | 0.88 | CYP1A2 (0.42) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1439543 | 0.88 | CYP1A2 (0.40) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1439540 | 0.88 | CYP1A2 (0.40) | CYP1A2POLBCYP3A4CYP2C19CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3909584-B1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-116368136-A | EGFR inhibitors | 大鹏药品工业株式会社 | 2023-06-30 | — | — | CN | disclosed |
| EP-4197538-A1 | EGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-06-21 | — | — | EP | disclosed |
| EP-4183395-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| WO-2012101063-A1 | N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101064-A1 | N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2473499-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | CYP1A2 974/4885POLB 690/4885CYP3A4 2004/4885 |
| US-20230285397-A1 | EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | CYP1A2 3686/4885POLB 4722/4885CYP3A4 4191/4885 |
| US-20230255972-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | TYMP, DPYD, TYMS | CYP1A2 3654/4885POLB 481/4885CYP3A4 2607/4885 |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CYP1A2 873/4885POLB 1063/4885CYP3A4 1058/4885 |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | CYP1A2 617/4885POLB 885/4885CYP3A4 817/4885 |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | CYP1A2 2152/4885POLB 244/4885CYP3A4 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.